Country: Canada
Language: English
Source: Health Canada
ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE)
NOVARTIS PHARMACEUTICALS CANADA INC
M05BA08
ZOLEDRONIC ACID
4MG
SOLUTION
ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE) 4MG
INTRAVENOUS
5ML
Prescription
BONE RESORPTION INHIBITORS
Active ingredient group (AIG) number: 0141761002; AHFS:
APPROVED
2003-12-05
_ZOMETA_ _®_ _ Product Monograph _ _Page 1 of 50 _ _ _ PRODUCT MONOGRAPH PR ZOMETA ® CONCENTRATE (Zoledronic acid for Injection) 4 mg zoledronic acid/5 mL incorporated as the monohydrate for intravenous infusion Bone Metabolism Regulator Novartis Pharmaceuticals Canada Inc. Dorval, Quebec H9S 1A9 Date of Revision: April 13, 2017 Control No. 200447 ZOMETA is a registered trademark _ZOMETA_ _®_ _ Product Monograph _ _Page 2 of 50 _ _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ..................................................................................................11 DRUG INTERACTIONS ..................................................................................................19 DOSAGE AND ADMINISTRATION ..............................................................................20 OVERDOSAGE ................................................................................................................24 ACTION AND CLINICAL PHARMACOLOGY ............................................................24 STORAGE AND STABILITY ..........................................................................................28 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................28 PART II: SCIENTIFIC INFORMATION ...............................................................................30 PHARMACEUTICAL INFORMATION ..........................................................................30 CLINICAL TRIALS ............................................... Read the complete document